Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Depressive Disorder, Major, Anxiety Disorder
In brief
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
Key facts
- Study ID
- NCT05232032
- Run by
- Mclean Hospital
- People needed
- 112
- Starts
- 2025-02-01
- Expected to finish
- 2027-03-31
- Last updated by the study team
- 2026-05-18
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Mclean Hospital — Belmont, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.